Mutations of the RAS/mitogen-activated protein kinase (MAPK) pathway, including NRAS, KRAS, or BRAF, are found in up to 50% of newly diagnosed MM patients (Walker et al., 2015), and contribute to proteasome inhibitor (PI) resistance (Shirazi et al., 2020). This evidence concerns the gene WNK2 and Miyoshi myopathy.